Cartesian Therapeutics

RNAC

Market cap $235M

RNAC Hedge Fund Activity: Q1 2026 in Review

83 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q1 2026, worth a combined $43.9M — up 18% from $37.2M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new RNAC positions and 10 closed out — a net gain of 18 holders — while 28 added to existing stakes and 15 trimmed.

The largest buyer was Squarepoint, adding an estimated $15.8M. The largest seller was Fidelity Investments, cutting an estimated $4.04M.

• 83 institutional investors held Cartesian Therapeutics (RNAC) as of Q1 2026, up from 67 in Q4 2025.
• Funds reported $43.9M of Cartesian Therapeutics stock for Q1 2026, up 18% quarter-over-quarter.
• 28 funds opened new Cartesian Therapeutics positions in Q1 2026 and 10 closed out, a net change of +18 holders.
• The largest Cartesian Therapeutics buyer in Q1 2026 was Squarepoint, an estimated $15.8M added.
• The largest Cartesian Therapeutics seller in Q1 2026 was Fidelity Investments, an estimated $4.04M sold.

Based on aggregated 13F filings for Q1 2026.